Results 61 to 70 of about 113,471 (74)

A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk

Acta Pharmacologica Sinica, 2022
Qun Cheng, Li You, Zhi-Jun Li
exaly  

Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial

BioDrugs, 2023
Huiping Li, Xiao-jia Wang, Xiangcai Wang
exaly  

A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects

Cancer Chemotherapy and Pharmacology, 2020
Jie Huang, Can Guo, Qi Pei
exaly  

Purification, Identification, and Properties of a Novel Carotenoid Produced by Arthrobacter sp. QL17 Isolated from Mount Qomolangma

Antioxidants, 2022
Xue Yu, Yujie Wu
exaly  

A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects

Frontiers in Pharmacology, 2020
Hong Zhang, Quan Liu, Wei Wei
exaly  

A randomized, double-blind, parallel control study to evaluate the biosimilarity of QL1209 with Perjeta® in healthy male subjects

Frontiers in Pharmacology, 2022
exaly  

Regulation of lysosome integrity and lysophagy by the ubiquitin-conjugating enzyme UBE2QL1

Autophagy, 2020
Hemmo H Meyer, Christian Behrends
exaly  

Activity-balanced GLP-1/GDF15 dual agonist reduces body weight and metabolic disorder in mice and non-human primates

Cell Metabolism, 2023
exaly  

Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-Related Macular Degeneration

Ophthalmology Retina
Agnieszka Nowosielska, , Ignasi Jürgens
exaly  

QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study

Signal Transduction and Targeted Therapy
Wenfeng Fang, Hongyun Zhao, Likun Chen
exaly